Less Ads, More Data, More Tools Register for FREE

Wednesday broker round-up

Wed, 01st Aug 2018 13:19
(Sharecast News) - Rightmove: Berenberg downgrades to sell with a target price of 4,100p.Pearson: Berenberg reiterates sell with a target price of 550p.GlaxoSmithKline: Berenberg reiterates buy with a target price of 1,790p.DCC: Berenberg reiterates buy with a target price of 8,700p.4imprint: Berenberg upgrades to hold with a target price of 1,925p.SSP Group: Canaccord upgrades to hold with a target price of 680p.Gocompare.com: Canaccord reiterates hold with a target price of 118p.Travis Perkins: Canaccord reiterates hold with a target price of 1,300p.Just Eat: Canaccord reiterates hold with a target price of 700p.Schroders: Berenberg reiterates hold with a target price of 3,420p.Sabre Insurance Group: Berenberg reiterates buy with a target price of 311p.IMI: Numis reiterates add with a target price of 1,400p.Man Group: Numis reiterates hold with a target price of 185p.St James's Place: Numis reiterates buy with a target price of 1,583p.Weir Group: Numis reiterates hold with a target price of 2,100p. Pearson Schroders Rightmove Man 4Imprint SSP Group Weir Group Travis Perkins Glaxosmithkline St James's Place DCC IMI Sabre Insurance Group

Shares in this article

Related News

European shares snap four-week winning streak on tech selloff, US-Iran war
1 day ago

European shares snap four-week winning streak on tech selloff, US-Iran war

* Renewed Middle East tensions keep investors on edge

Market News Soitec + 6 more shares
LONDON MARKET CLOSE: Vodafone lifts FTSE 100 as easyJet backs new bid
1 day ago

LONDON MARKET CLOSE: Vodafone lifts FTSE 100 as easyJet backs new bid

(Alliance News) - The FTSE 100 closed higher on Friday in calmer trading, boosted by double-digit gains from telecommunications firm Vodafone.

Market News Vodafone + 12 more shares
GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
1 day ago

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial

* GSK partner Hansoh reports first late-stage data ​for experimental ⁠lung cancer drug